Defeating the Highly Potent Toxicity of ADCs Targeting TGF-β for Effective Patient Response
Time: 9:00 am
day: Conference Day Two
Details:
- Evolving the ALK5 inhibitor payload to achieve patient treatment success
- Targeting TGF-β receptors using ADC to avoid toxicity in the heart and bone
- Avoiding systematic toxicity in TGF-β directed therapies by highly specific targeting for better patient response
